Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHAT | P28329 | 4/20 | 0.48 |
| ▸ | CNR1 | P21554 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL304242 | 0.95 | CHAT (0.50) | CHATCNR1GAATDP1L3MBTL1 | |
| SCHEMBL304218 | 0.93 | CHAT (0.52) | CHATCNR1GAATDP1L3MBTL1 | |
| SCHEMBL303925 | 0.93 | CHAT (0.52) | CHATCNR1GAATDP1L3MBTL1 | |
| SCHEMBL302714 | 0.93 | CHAT (0.52) | CHATCNR1GAATDP1L3MBTL1 | |
| SCHEMBL303784 | 0.93 | CHAT (0.52) | CHATCNR1GAATDP1L3MBTL1 | |
| SCHEMBL303905 | 0.93 | CHAT (0.52) | CHATCNR1GAATDP1L3MBTL1 | |
| SCHEMBL302668 | 0.93 | CHAT (0.52) | CHATCNR1GAATDP1L3MBTL1 | |
| SCHEMBL303704 | 0.93 | CHAT (0.52) | CHATCNR1GAATDP1L3MBTL1 | |
| SCHEMBL302934 | 0.93 | CHAT (0.52) | CHATCNR1GAATDP1L3MBTL1 | |
| SCHEMBL304715 | 0.93 | CHAT (0.52) | CHATCNR1GAATDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 436 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1038863-B1 | Substituted dimeric compounds, process for their preparation and pharmaceutical compositions thereof | SERVIER LAB (FR) | 2003-06-04 | — | — | EP | claimed |
| EP-1057826-B1 | Substituted dimeric carboxamide derivatives, method for preparing them, and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2003-04-16 | — | — | EP | claimed |
| EP-4234609-B1 | METHODS FOR PURIFICATION, DETECTION AND QUANTIFICATION OF RESIDUAL PEI-BASED TRANSFECTION REAGENTS | POLYPLUS TRANSFECTION (FR) | 2024-07-17 | — | — | EP | disclosed |
| EP-4019607-B1 | ELECTROCHROMIC COMPOUNDS AND OPTICAL ARTICLES CONTAINING THEM | ESSILOR INT (FR) | 2024-05-15 | — | — | EP | disclosed |
| US-20240052235-A1 | ELECTROCHROMIC COMPOUNDS AND OPTICAL ARTICLES CONTAINING THEM | ESSILOR INTERNATIONAL (FR) | 2024-02-15 | — | — | US | disclosed |
| CN-117551696-A | Composition for transfecting nucleic acid molecules into cells comprising triazole compounds grafted onto cationic polymers and uses thereof | 宝利普拉斯生物转染公司 | 2024-02-13 | — | — | CN | disclosed |
| CN-114901316-B | Composition for transfecting nucleic acid molecules into cells comprising triazole compounds grafted onto cationic polymers and uses thereof | 宝利普拉斯生物转染公司 | 2024-02-13 | — | — | CN | disclosed |
| US-11879001-B2 | Conjugate comprising an IL-2 moiety | Ascendis Pharma Oncology Division A/S (DK) | 2024-01-23 | — | — | US | disclosed |
| US-20230340055-A1 | GLYCOSYLATED IL-2 PROTEINS AND USES THEREOF | Ascendis Pharma Oncology Division A/S (DK) | 2023-10-26 | — | — | US | disclosed |
| CN-116783168-A | Electrochromic compounds and optical articles comprising the same | 依视路国际公司 | 2023-09-19 | — | — | CN | disclosed |
| WO-2023161409-A1 | METHODS FOR PURIFICATION, DETECTION AND QUANTIFICATION OF RESIDUAL PEI-BASED TRANSFECTION REAGENTS | POLYPLUS TRANSFECTION (FR) | 2023-08-31 | — | — | WO | disclosed |
| WO-1993009077-A2 | PROCESS FOR THE PREPARATION OF FLUORINATED BENZOIC ACIDS | ABBOTT LABORATORIES (US) | 1993-05-13 | — | — | WO | disclosed |
| EP-0503785-A1 | 1-Biphenylimidazole derivatives, their preparation and their therapeutic use | Sankyo Company Limited (JP) | 1992-09-16 | — | — | EP | disclosed |
| EP-0501656-A2 | New benzene derivatives having (NGF) production-promoting activity | Sankyo Company Limited (JP) | 1992-09-02 | — | — | EP | disclosed |
| EP-0498680-A1 | New beta-amino-alpha-hydroxycarboxylic acids and their use | Sankyo Company Limited (JP) | 1992-08-12 | — | — | EP | disclosed |
| WO-1992009564-A1 | PEPTIDYL DERIVATIVES | CELLTECH LIMITED (GB) | 1992-06-11 | — | — | WO | disclosed |
| WO-1992009565-A1 | PEPTIDYL DERIVATIVES | CELLTECH LIMITED (GB) | 1992-06-11 | — | — | WO | disclosed |
| EP-0489577-A1 | Peptidyl derivatives | CELLTECH LIMITED (GB) | 1992-06-10 | — | — | EP | disclosed |
| EP-0489579-A1 | Peptidyl derivatives | CELLTECH THERAPEUTICS LIMITED (GB) | 1992-06-10 | — | — | EP | disclosed |
| US-4329350-A | VASODILATORS | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1982-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340055-A1 | GLYCOSYLATED IL-2 PROTEINS AND USES THEREOF | IL2, IL1A, ILF2 | CHAT 2571/4885CNR1 4767/4885GAA 1133/4885 |
| US-11879001-B2 | Conjugate comprising an IL-2 moiety | IL2, IL2RA, IL4I1 | CHAT 2626/4885CNR1 4105/4885GAA 4063/4885 |
| US-20240052235-A1 | ELECTROCHROMIC COMPOUNDS AND OPTICAL ARTICLES CONTAINING THEM | EYA3, LAGE3, CDKL5 | CHAT 153/4885CNR1 1691/4885GAA 4365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.